Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
GlycoMimetics (GLYC) has issued an update.
GlycoMimetics, Inc. announced significant findings from its Phase 3 trial of uproleselan, targeting relapsed/refractory acute myeloid leukemia, and held a live webcast to discuss these outcomes. While detailed results were shared, this information is for disclosure purposes and will not be considered officially filed or integrated into prior or future securities filings, unless explicitly stated.
Find detailed analytics on GLYC stock on TipRanks’ Stock Analysis page.